Substrate-dependent ligand inhibition of the human organic cation transporter OCT2

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 2, 2013, Pages 300-310

  Belzer, Mathew ^a   Morales, Mark ^a   Jagadish, Bhumasamudram ^a   Mash, Eugene A ^a   Wright, Stephen H ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMITRIPTYLINE; CARVEDILOL; CHLOROQUINE; CIMETIDINE; CLONIDINE; DIPHENHYDRAMINE; DISOPYRAMIDE; FLECAINIDE; FLUORESCENT DYE; IMIPRAMINE; IPRATROPIUM BROMIDE; METFORMIN; N,N,N TRIMETHYL 2 [METHYL (7 NITROBENZO[C][1,2,5]OXADIAZOL 4 YL)AMINO]ETHANAMINIUM IODIDE; OCTAMER TRANSCRIPTION FACTOR 2; PROPAFENONE; PROPRANOLOL; QUINIDINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; BINDING COMPETITION; BINDING SITE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TRANSPORT; EMBRYO; FEMALE; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TRANSPORT KINETICS;

EID: 84880428300     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203257     Document Type: Article

References (44)

1. Aavula BR, Ali MA, Bednarczyk D, Wright SH, and Mash EA (2006) Synthesis and fluorescence of n,n,n-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4- yl)amino]ethanaminium iodide, a ph-insensitive reporter of organic cation transport. Synth Commun 36:701-705.
2. Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CA, and Artursson P (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem 51: 5932-5942.
3. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, and Urbatsch IL, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722.
4. Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bönisch H, and Gautron S (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941-952.
5. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, and Stricker BH (2007) Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16:641-651.
6. Bednarczyk D, Ekins S, Wikel JH, and Wright SH (2003) Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 63:489-498.
7. Bednarczyk D, Mash EA, Aavula BR, and Wright SH (2000) NBD-TMA: a novel fluorescent substrate of the peritubular organic cation transporter of renal proximal tubules. Pflugers Arch 440:184-192.
8. Egenberger B, Gorboulev V, Keller T, Gorbunov D, Gottlieb N, Geiger D, Mueller TD,, and Koepsell H (2012) A substrate binding hinge domain is critical for transportrelated structural changes of organic cation transporter 1. J Biol Chem 287: 31561-31573.
9. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, and Schuetz JD, et al. (2002) Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981.
10. Endres CJ, Hsiao P, Chung FS, and Unadkat JD (2006) The role of transporters in drug interactions. Eur J Pharm Sci 27:501-517.
11. Garrigues A, Loiseau N, Delaforge M, Ferté J, Garrigos M, André F, and Orlowski S (2002) Characterization of two pharmacophores on the multidrug transporter Pglycoprotein. Mol Pharmacol 62:1288-1298.
12. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
13. Gorboulev V, Volk C, Arndt P, Akhoundova A, and Koepsell H (1999) Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate. Mol Pharmacol 56:1254-1261.
14. Groves CE, Evans KK, Dantzler WH, and Wright SH (1994) Peritubular organic cation transport in isolated rabbit proximal tubules. Am J Physiol 266:F450-F458.
15. Harper JN and Wright SH (2013) Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am J Physiol Renal Physiol 304: F56-F67.
16. Kido Y, Matsson P, and Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548-4558.
17. Lee WK, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H, and Thévenod F (2009) Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule. Am J Physiol Renal Physiol 296:F1504-F1513.
18. Lepist EI and Ray AS (2012) Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol 8:433-448.
19. Lin S and Struve WS (1991) Time-resolved fluorescence of nitrobenzoxadiazoleaminohexanoic acid: effect of intermolecular hydrogen-bonding on non-radiative decay. Photochem Photobiol 54:361-365.
20. Malo C and Berteloot A (1991) Analysis of kinetic data in transport studies: new insights from kinetic studies of Na(1)-D-glucose cotransport in human intestinal brush-border membrane vesicles using a fast sampling, rapid filtration apparatus. J Membr Biol 122:127-141.
21. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, and Martinez-Picado J (2009) Transport of lamivudine [(-)-beta-L-29,39-dideoxy-39-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 329:252-261.
22. Moaddel R, Ravichandran S, Bighi F, Yamaguchi R, and Wainer IW (2007) Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1). Br J Pharmacol 151:1305-1314.
23. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, and Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-874.
24. Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H, and Brandsch M (2005) Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70:1851-1860.
25. Neuhoff S, Ungell AL, Zamora I, and Artursson P (2003) pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drugdrug interactions. Pharm Res 20:1141-1148.
26. Nies AT, Koepsell H, Damme K, and Schwab M (2011) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handbook Exp Pharmacol 201:105-167.
27. Pelis RM, Dangprapai Y, Cheng Y, Zhang X, Terpstra J, and Wright SH (2012) Functional significance of conserved cysteines in the human organic cation transporter 2. Am J Physiol Renal Physiol 303:F313-F320.
28. Pelis RM, Dangprapai Y, Wunz TM, and Wright SH (2007) Inorganic mercury interacts with cysteine residues (C451 and C474) of hOCT2 to reduce its transport activity. Am J Physiol Renal Physiol 292:F1583-F1591.
29. Pelis RM, Zhang X, Dangprapai Y, and Wright SH (2006) Cysteine accessibility in the hydrophilic cleft of human organic cation transporter 2. J Biol Chem 281: 35272-35280.
30. Popp C, Gorboulev V, Müller TD, Gorbunov D, Shatskaya N, and Koepsell H (2005) Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol 67:1600-1611.
31. Roth M, Timmermann BN, and Hagenbuch B (2011) Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos 39:920-926.
32. Schumacher MA and Brennan RG (2003) Deciphering the molecular basis of multidrug recognition: crystal structures of the Staphylococcus aureus multidrug binding transcription regulator QacR. Res Microbiol 154:69-77.
33. Segel IH (1975) Enzyme Kinetics, pp 100-135, John Wiley & Sons, New York.
34. Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, and Figg WD (2012) Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy. Discov Med 13:19-34.
35. Suhre WM, Ekins S, Chang C, Swaan PW, and Wright SH (2005) Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol 67:1067-1077.
36. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, and Sugiyama Y (2005) A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315:337-345.
37. Thummel KE and Shen DD (2001) Design and optimization of dosage regimens: pharmacokinetic data, in Goodman & Gilman's: The Pharmacological Basis of Therapeutics (Hardman JG and Limbird LE, eds, ed) pp 1917-2023, McGraw-Hill, New York.
38. Ullrich KJ (1997) Renal transporters for organic anions and organic cations: structural requirements for substrates. J Membr Biol 158:95-107.
39. Volk C, Gorboulev V, Budiman T, Nagel G, and Koepsell H (2003) Different affinities of inhibitors to the outwardly and inwardly directed substrate binding site of organic cation transporter 2. Mol Pharmacol 64:1037-1047.
40. Volk C, Gorboulev V, Kotzsch A, Müller TD, and Koepsell H (2009) Five amino acids in the innermost cavity of the substrate binding cleft of organic cation transporter 1 interact with extracellular and intracellular corticosterone. Mol Pharmacol 76: 275-289.
41. Westholm DE, Salo DR, Viken KJ, Rumbley JN, and Anderson GW (2009) The bloodbrain barrier thyroxine transporter organic anion-transporting polypeptide 1c1 displays atypical transport kinetics. Endocrinology 150:5153-5162.
42. Zhang X, He X, Baker J, Tama F, Chang G, and Wright SH (2012) Twelve transmembrane helices form the functional core of mammalian MATE1 (multidrug and toxin extruder 1) protein. J Biol Chem 287:27971-27982.
43. Zhang X, Shirahatti NV, Mahadevan D, and Wright SH (2005) A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2). J Biol Chem 280:34813-34822.
44. Zolk O, Solbach TF, König J, and Fromm MF (2009) Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 379:337-348.